Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800)

Micro-Abstract The use of atrasentan, an endothelin receptor A antagonist, was studied in cohorts of patients with renal cell carcinoma (RCC) with and without prior immunotherapy and either measurable disease or bone metastases only in the pre-VEGF/TKI era. Although well tolerated, atrasentan did no...

Full description

Saved in:
Bibliographic Details
Published in:Clinical genitourinary cancer 2015-12, Vol.13 (6), p.531-539.e1
Main Authors: Carducci, Michael A, Manola, Judith, Nair, Suresh G, Liu, Glenn, Rousey, Steven, Dutcher, Janice P, Wilding, George
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Atrasentan
Bone metastases
Bone Neoplasms - drug therapy
Bone Neoplasms - secondary
Carcinoma, Renal Cell - drug therapy
Disease-Free Survival
Endothelin A receptor antagonist
Endothelin Receptor Antagonists - administration & dosage
Endothelin Receptor Antagonists - adverse effects
Female
Hematology, Oncology and Palliative Medicine
Humans
Kidney cancer
Kidney Neoplasms - drug therapy
Male
Middle Aged
Pain palliation
Progression-free survival
Pyrrolidines - administration & dosage
Pyrrolidines - adverse effects
Treatment Outcome
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract The use of atrasentan, an endothelin receptor A antagonist, was studied in cohorts of patients with renal cell carcinoma (RCC) with and without prior immunotherapy and either measurable disease or bone metastases only in the pre-VEGF/TKI era. Although well tolerated, atrasentan did not yield 6-month progression-free rates supporting its use as first-line monotherapy in patients with advanced RCC.
ISSN:1558-7673
1938-0682
DOI:10.1016/j.clgc.2015.07.002